Wall Street Zen Upgrades Cardiff Oncology Stock Rating

The biopharmaceutical company's stock rating improved from 'sell' to 'hold'.

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Cardiff Oncology (NASDAQ:CRDF), a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapies to modulate the tumor microenvironment and enhance antitumor immune responses, has had its stock rating upgraded from 'sell' to 'hold' by research analysts at Wall Street Zen. Several other brokerages have also recently weighed in on CRDF, with Piper Sandler lowering their target price and Noble Financial initiating coverage with an 'outperform' rating.

Why it matters

The rating upgrade from Wall Street Zen, along with the mixed views from other analysts, reflects the ongoing uncertainty and volatility surrounding Cardiff Oncology's stock performance. As a clinical-stage biotech company, its fortunes are closely tied to the progress and success of its pipeline of experimental cancer therapies, which can significantly impact investor sentiment and the stock price.

The details

Wall Street Zen upgraded Cardiff Oncology's stock rating from 'sell' to 'hold' in a research note issued to investors on Wednesday. Several other brokerages have also recently weighed in on CRDF, with Piper Sandler lowering their target price from $10.00 to $6.00 and maintaining an 'overweight' rating, while Noble Financial initiated coverage with an 'outperform' rating and a $12.00 price target. Weiss Ratings reissued a 'sell (d-)' rating, and HC Wainwright restated a 'buy' rating with a $10.00 target price.

  • Cardiff Oncology released its quarterly earnings results on Tuesday, February 24th.
  • Noble Financial initiated coverage on Cardiff Oncology on Monday, January 5th.
  • Weiss Ratings reissued a 'sell (d-)' rating on Wednesday, January 21st.
  • HC Wainwright restated a 'buy' rating on Wednesday, January 28th.
  • Piper Sandler lowered their target price on Wednesday, February 25th.

The players

Wall Street Zen

A research firm that provides analysis and ratings on publicly traded companies.

Cardiff Oncology

A clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses.

Piper Sandler

A financial services firm that provides investment banking, asset management, and other financial services.

Noble Financial

A financial services firm that provides investment research, trading, and investment banking services.

Weiss Ratings

A financial research and ratings agency that provides independent analysis and ratings on various financial products and services.

HC Wainwright

A financial services firm that provides investment banking, equity research, and corporate access services.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The mixed analyst views on Cardiff Oncology's stock reflect the inherent volatility and uncertainty surrounding clinical-stage biotech companies, whose fortunes are closely tied to the progress and success of their experimental drug pipelines. Investors will likely continue to closely monitor Cardiff Oncology's developments as it seeks to advance its novel cancer therapies through the clinical trial process.